<DOC>
	<DOCNO>NCT03098836</DOCNO>
	<brief_summary>The primary goal prospectively estimate median PFS African American Caucasian men mCRPC take apalutamide , abiraterone acetate , prednisone . Secondary objective include : PSA kinetics : determine duration PSA response , time nadir , percent men achieve PSA &lt; 0.1 ; Radiographic assessment : estimate rate objective response incidence bone flare ; Safety ( NCI CTC v4.0 ) tolerability , particularly incidence grade hypertension two population . This non-comparative pilot open-label , parallel arm , multicenter study apalutamide abiraterone acetate African American Caucasian men mCRPC . It anticipate 3 additional site need accrue 100 subject ( 50 African American 50 Caucasian ) 24 month accrual period . The study agent administerd follow dos : apalutamide 240mg orally daily , abiraterone acetate 1000mg orally daily , prednisone 5 mg BID 4-week cycle throughout treatment period . Fifty ( 50 ) patient enrol group ( AA Caucasians ) . The proportion patient experience PSA decline 30 % , 50 % 90 % estimate exact 95 % confidence interval base binomial distribution compute . In addition , post therapy change PSA explore continuous outcome . The Kaplan-Meier product limit method use estimate rPFS , biochemical PFS overall survival distribution .</brief_summary>
	<brief_title>Apalutamide Abiraterone Acetate African American Caucasian Men With Metastatic Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Male , age ≥ 18 year 2 . Karnofsky performance status ≥ 70 ( Appendix 1 ) 3 . Life expectancy ≥ 12 month determine treat investigator 4 . Written Authorization Use Release Health Research Study Information ( HIPAA authorization per institutional requirement ) 5 . Willing/able adhere prohibition restriction specify protocol 6 . Willing take abiraterone acetate empty stomach , able swallow tablet whole , without crushing/chewing tablet . Must ability swallow , retain , absorb oral medication . 7 . Medications know low seizure threshold ( see list prohibit med , appendix 2 ) must discontinue substitute least 4 week prior study entry 8 . Agrees use condom ( even men vasectomy ) another effective method birth control sex woman childbearing potential agrees use condom sex woman pregnant study drug 3 month follow last dose study drug . Must also agree donate sperm study 3 month receive last dose study drug . Abstinence acceptable method birth control . 9 . Adequate bone marrow function show : ANC ≥ 1.0 x 109/L , Platelets ≥ 100 x 109/L , Hb≥9 g/dL , ( independent transfusion and/or growth factor within 3 month prior randomization ) 10 . Serum potassium ≥ 3.5 mEq/L 11 . Serum albumin ≥ 3.0 g/dl 12 . AST/SGOT ALT/SGPT &lt; 2.5 x Institutional Upper Limit Normal ( ULN ) 13 . Serum total bilirubin ≤ 1.5 x Institutional ULN ( Note : In subject Gilbert 's syndrome , total bilirubin &gt; 1.5 × ULN , measure direct indirect bilirubin direct bilirubin ≤1.5 × ULN , subject may eligible ) 14 . GFR ≥45 mL/min 15 . Histologically confirm diagnosis adenocarcinoma prostate . Histologic variant prostate cancer comprise &gt; 50 % tumor include neuroendocrine feature small cell carcinoma prostate exclude . 16 . Radiographic evidence metastatic disease base RECIST 1.1 Criteria 17 . Ongoing ADT use LHRH agonist ( e.g . leuprolide , goserelin ) antagonist ( e.g . degarelix ) must continue therapy unless prior bilateral orchiectomy perform . 18 . Screening serum testosterone must &lt; 50 ng/dL . 19 . PSA ≥ 2.0 ng/mL 20 . Evidence castration resistant disease ADT evidence one following : Absolute rise PSA 2.0 ng/mL increase &gt; 25 % , minimum 2 consecutive rise PSA level interval ≥ 1 week PSA level , OR 2 consecutive PSA level 50 % great PSA nadir achieve ADT separate least 1 week apart , OR CT MRI base evidence disease progression ( soft tissue , nodal visceral disease progression ) accord PCWG3 criterion RECIST 1.1 criterion , OR At least 1 new bone scan lesion compare immediate prior radiologic study . 21 . A minimum 2 week elapse antiandrogen therapy prior start study drug ( i.e . flutamide , nilutamide , bicalutamide . ) 22 . A minimum 2 week elapse sipuleucelT radiation therapy prior start study drug 23 . A minimum 4 week major surgery prior start study drug . 24 . Selfreported race either African American Caucasian . 25 . Ability understand willingness sign write informed consent document . If subject unable understand consent due comorbidity , Alzheimer 's disease , consent legally authorize representative assent subject obtain . 1 . Prior treatment abiraterone acetate , enzalutamide , apalutamide ( ARN509 ) , galaterone ( TOK001 ) , orteronel ( TAK700 ) , similar agent 2 . Active infection medical condition would make prednisone/prednisolone ( corticosteroid ) use contraindicate 3 . Active symptomatic infection include HIV , viral hepatitis chronic liver disease 4 . Any chronic medical condition require high dose corticosteroid 5mg prednisone/prednisolone bid 5 . Have know allergy , hypersensitivity , intolerance abiraterone acetate , apalutamide prednisone excipients . 6 . Pathological find consistent small cell carcinoma prostate 7 . Symptomatic liver visceral organ metastasis 8 . Have history gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study agent 9 . Known brain metastasis 10 . Prior cytotoxic chemotherapy biologic therapy treatment CRPC 11 . Previously treat ketoconazole prostate cancer great 7 day 12 . Prior systemic treatment azole drug ( e.g . fluconazole , itraconazole ) within 4 week Cycle 1 , Day 1 . 13 . Uncontrolled hypertension ( systolic BP ≥ 140 mmHg diastolic BP ≥ 90 mmHg ) . Patients history hypertension allow provide blood pressure control antihypertensive treatment 14 . Poorly control diabetes , FBS ≥200 mg/dL 15 . History pituitary adrenal dysfunction 16 . Symptomatic Atrial Fibrillation , symptomatic cardiac arrhythmia 17 . Other malignancy , except nonmelanoma skin cancer , ≥ 30 % probability recurrence within 24 month 18 . History follow : Seizure know condition may predispose seizure ( e.g . prior stroke within 1 year randomization , brain arteriovenous malformation , Schwannoma , meningioma , benign CNS meningeal disease may require treatment surgery radiation therapy ) Severe unstable angina , myocardial infarction , symptomatic congestive heart failure , arterial venous thromboembolic event ( e.g. , pulmonary embolism , cerebrovascular accident include transient ischemic attack ) , clinically significant ventricular arrhythmia within 6 month prior first dose study drug . 19 . Avoid concomitant strong CYP3A4 inducer abiraterone acetate treatment . 20 . Avoid coadministration abiraterone acetate CYP2D6 substrates narrow therapeutic index . If alternative treatment use , exercise caution consider dose reduction concomitant CYP2D6 substrate 21 . Baseline moderate severe hepatic impairment ( Child Pugh Class B &amp; C ) 22 . Use herbal product may decrease PSA level ( i.e. , saw palmetto ) refer section 8.6 23 . Administration investigational therapeutic within 30 day prior Cycle 1 , Day 1 24 . Any condition , opinion investigator , would preclude participation trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>castrate resistant</keyword>
</DOC>